ask our doctors

Polycythemia Vera

Get the facts on Polycythemia Vera treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Polycythemia Vera prevention, screening, research, statistics and other Polycythemia Vera related topics. We answer all your qestions about Polycythemia Vera.

Question: Polycythemia vera? One of my very close friend have the problem of "Polycythemia vera" . any one there to suggest any medicine of any way to solve this?

Answer: Polycythemia vera : Alternative names Primary polycythemia; Polycythemia rubra vera; Myeloproliferative disorder; Erythremia; Splenomegalic polycythemia; Vaquez's disease; Osler's disease; Polycythemia with chronic cyanosis - Myelopathic polycythemia; Erythrocytosis megalosplenica; Cryptogenic polycythemia Definition : Polycythemia vera is an abnormal increase in blood cells (primarily red blood cells) resulting from excess production by the bone marrow. Causes, incidence, and risk factors : Polycythemia vera is an acquired disorder of the bone marrow that causes the overproduction of all three blood cell lines: white blood cells, red blood cells, and platelets. It is a rare disease that occurs more frequently in men than women, and rarely in patients under 40 years old. It is not known what causes polycythemia vera. The disease usually develops slowly, and most patients do not experience any problems related to the disease after being diagnosed. However, the abnormal bone marrow cells may begin to grow uncontrollably in some patients leading to acute myelogenous leukemia. Patients with polycythemia vera also have an increased tendency to form blood clots that can result in strokes or heart attacks. Some patients may experience abnormal bleeding because their platelets are abnormal. Symptoms : Headache Dizziness Itchiness, especially following a warm bath Fullness in the left upper abdomen Red coloration, especially of the face Shortness of breath Breathing difficulty when lying down Symptoms of phlebitis Note: Symptoms are due to increased blood viscosity (thickness) and clotting. Additional symptoms that may be associated with this disease: Vision abnormalities Skin spots, red Bluish skin discoloration Fatigue Signs and tests Return to top A CBC with differential Hematocrit, elevated White blood count, elevated Platelet count, elevated Bone marrow biopsy Vitamin B-12 level Chemistry panel Blood volume, increased This disease may also alter the results of the following tests: Lactate dehydrogenase Urinalysis Serum uric acid TIBC RBC count Platelet aggregation test Leukocyte alkaline phosphatase Hemoglobin ESR Erythropoietin Treatment : -The objective of treatment is to reduce the high blood viscosity (thickness of the blood) due to the increased red blood cell mass and to prevent hemorrhage and thrombosis. -Phlebotomy is one method used to reduce the high blood viscosity. In phlebotomy, 1 unit (pint) of blood is removed weekly until the hematocrit is less than 45, then phlebotomy is continued as necessary. -Occasionally, chemotherapy may be given to suppress the bone marrow. Other agents such as interferon may be given to lower blood counts. Anegrelide may be given to lower platelet counts. -The use of anti-platelet therapy (such as aspirin) is controversial because it may cause stomach bleeding. -Allopurinol is given for hyperuricemia (gout). Expectations (prognosis) : Polycythemia vera usually develops slowly, and most patients treated appropriately do not experience any problems related to the disease. However, the abnormal bone marrow cells may begin to grow uncontrollably leading to acute myelogenous leukemia. This occurs in a minority of cases. Patients with polycythemia vera also have an increased tendency to form blood clots that can result in strokes or heart attacks. Some patients may experience abnormal bleeding because their platelets are abnormal. Complications Thrombosis (a cause of stroke or heart attack) Peptic ulcer disease Gastric bleeding Gout Leukemia Heart failure Myelofibrosis


Polycythemia Vera News

Newsolio (blog)

What is polycythemia vera? How do you get it? What are its symptoms? Is it ...
Newsolio (blog)
 

CHMP recommends EU approval for Novartis' Jakavi to treat patient with ...

pharmabiz.com
As part of the Novartis clinical development programme, Jakavi is being investigated in primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Jakavi is also being investigated in clinical trials ...
 

Researchers making new push in cancer cluster search

WSBT-TV
Polycythemia vera puts the body's blood-producing cells into overdrive, clogging arteries with up to five times as many red blood cells as normal. Itching, headaches and fatigue are the milder symptoms ? if left untreated, the cancer can form fatal ...
 

Incyte looks to ride on drug's success

The News Journal
Jakafi is in the final stage of study for the treatment of polycythemia vera, a blood disorder related to myelofibrosis that affects a larger population. The firm expects to file and receive approval in 2013 and 2014. "We'll be watching to see over the ...
 

Incyte achieves regulatory milestone under ruxolitinib license agreement with ...

Pharmaceutical Business Review
The recommendation by the CHMP of the EMA for approval of ruxolitinib to treat of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia ...
 

Incyte's CEO Bank of America Merrill Lynch 2012 Health Care Conference ...

Seeking Alpha
And beyond its development in myelofibrosis, we are studying ruxolitinib in a number of other indications that could add to its therapeutic and commercial value and most advanced is the clinical development in polycythemia vera, it's another ...
 

Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover ...

Seeking Alpha
In addition, INCY has seen a strong launch of Jakafi -- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia ...
 

Analyst says Incyte's pipeline makes it attractive takeover candidate

Proactive Investors USA & Canada
In addition, INCY has seen a strong launch of Jakafi-- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post?polycythemia vera myelofibrosis and post?essential thrombocythemia ...
 

Incyte's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Seeking Alpha
In addition to the ongoing extensions of our Phase II and Phase III trials in MF, Incyte and Novartis are conducting a global pivotal Phase III trial called RESPONSE in patients with advance polycythemia vera and we continue to expect the RESPONSE ...
 

Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients ...

PipelineReview.com (press release)
... for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.